Resistance/sensitivity in vitro in ovarian cancer patients

Česká verzia

Authors: I. Sedláková ¹; J. Tošner ¹; A. Řezáč ¹; M. Červinka ²; K. Brigulová ²; J. Špaček ¹; M. Tomšová ³; P. Škapinec ¹
Authors place of work: Porodnická a gynekologická klinika LF UK a FN, Hradec Králové, přednosta doc. MUDr. J. Tošner, CSc. ¹; Ústav biologie a lékařské genetiky, Lékařská fakulta v Hradci Králové UK Praha, přednosta prof. MUDr. RNDr. M. Červinka, CSc. ²; Fingerlandův patologický ústav FN, Hradec Králové, přednosta prof. MUDr. A. Ryška, Ph. D. ³
Published in the journal: Ceska Gynekol 2010; 75(3): 182-187

Summary

Objective:
To assay resistance/sensitivity by MTT test in solid tumor or ascitic fluid in ovarian cancer patients.

Design:
Prospective study.

Setting:
Department of Gynecology and Obstetrics, Medical Faculty Charles University, Prague and University Hospital, Hradec Králové.

Methods:
MTT – (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) chemosensitivity assay was performed in 32 samples of ovarian cancer tissue and 26 samples of ascitic fluid in ovarian cancer patients. We studied the in vitro drug resistance profiles of ovarian cancer specimens exposed to cisplatin, carboplatin, paclitaxel, topotecan, gemcitabin, etoposid.

Results:
The highest frequency of resistance in vitro occured for etoposid, gemcitabin and paclitaxel and the most effective chemotherapeutical agents in vitro were cisplatinum and topotecan. Cisplatin had the lowest incidence of drug resistance in vitro than carboplatin.

Conclusion:
Resistance/sensitivity assay would improve the treatment and prognosis of ovarian cancer patients.

Key words:
ovarian cancer, resistance, sensitivity, chemotherapeutic agent, MTT assay.

Zdroje

1. Cloven, NG., Kyshtoobayeva, A., Burger, AR., et al. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol, 2004, 92, p. 160-166.

2. Dvorská, M., Driák, D., Švandová, I. Apoptóza v gynekologii a porodnictví. Gynekolog, 2008, 4, s. 132-140.

3. Fruehauf, JP., Alberts, SD. In vitro drug resistance versus chemosensitivity: Two sides of different coins. J Clin Oncol, 2005, 23, p. 3641-3643.

4. Geisler, JP., Linnemeier, CG., Thomas, JA,. et al. Extreme drug resistance is common after prior exposure to paclitaxel. Gynecol Oncol, 2007, 106, p. 538-540.

5. Holloway, RW., Mehta, RS., Finkler, NJ., et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol, 2002, 87, p. 8-16.

6. Kostečka, A., Vagundová, M. Prediktivní testy chemorezistence in vitro. Souhrnná roční zpráva o řešení výzkumného záměru MOÚ v Brně, 2003, s. 36-38.

7. Lichý, JH., Dalbergue, F., Washington, C., et al. Genetic heterogenity in ductal carcinoma of the breast. LabInvest, 2000, 80, p. 291-301.

8. Metzinger, SD., Taylor, DD., Taylor, GC. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines. Cancer Letters, 2006, 236, p. 302-308.

9. Michalová, E., Poprach, A., Němečková, I., et al. Predikce citlivosti nádorových buněk k chemoterapeutikům ex vivo – úskalí a limitace vlastní metody. Klin Onkol, 2008, 21, s. 93-97.

10. Ozols, FR. Paclitaxel(Taxol)/carboplatina combination chemotherapy in the treatment of advanced ovarian cancer. Seminars in Oncology, 2000, 3, p. 3-7.

11. Perez, RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer, 1998, 34, p. 1535-1542.

12. Sedláková, I., Tošner, J., Špaček, J., et al. Chemorezistence/chemosenzitivita ovariálního karcinomu – kazuistika. Čes Gynek, 2008, 3, s. 140-143.

13. Talač, R., Žaloudík, J., Hajdúch, M., et al. Hodnocení lékové rezistence in vitro a její klinické implikace. Klin Onkol, 2002, 2, s. 2-3.

14. Tewari, SK., Mehta, SR., Burger, AR., et al. Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecol Oncol, 2005, 98, p. 360-368.

15. Wu, H., Cao, Y., Weng, D., et al. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Letters, 2008, 271, p. 260-271.